Armistice Capital Holds Stakes in CNS and Cardiovascular Drug Developers Alongside Fellow Institutions
OnArmistice Capital, which manages more than $7 billion in assets, holds disclosed positions across both central nervous system and cardiovascular drug developers, reflecting a.
Read More